We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ROMIDEPSIN-MSN, ROMIDEPSIN-REACH (Reach Pharmaceuticals Pty Ltd)
Product name
ROMIDEPSIN-MSN, ROMIDEPSIN-REACH
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
133 (255 working days)
Active ingredients
Romidepsin
Registration type
New generic medicine
Indication
ROMIDEPSIN-MSN, ROMIDEPSIN-REACH is indicated for the treatment of peripheral T-cell lymphoma in patients who have received at least one prior systemic therapy.
Registration process
First generic
First approval of a medicine that contains the same active ingredient as and is bioequivalent to an existing medicine